11th Jan 2022 08:41
(Alliance News) - Dechra Pharameuticals PLC announced on Tuesday it will acquire the worldwide rights to canine medicine verdinexor, in an agreement with Anivive Lifesciences Inc.
The Cheshire-based specialist veterinary pharmaceutical business now has global product rights and a first right of refusal for other species for the medicine, which is used to treat of all forms and stages of canine lymphoma in dogs, as well as the trademark 'Laverdia'.
Dechra has said it will acquire worldwide marketing and intellectual property rights, associated regulatory documents, third-party supply contracts related to raw materials and the manufacture of the drug, and marketing authorisations, when these granted.
No other assets are being transferred to Dechra. Neither the price tag nor the timeline for the acquisition was specified.
The novel canine lymphoma medicine, currently sold as Laverdia-Ca1, was conditionally approved by the Food & Drug Administration Center for Veterinary Medicine back in January last year and started sales in the US in July. Full dossier submissions are planned for the US, UK, EU, Brazil, Australia, Japan and Canada.
Dechra Chief Executive Officer Ian Page commented: "We are delighted to acquire the worldwide rights to Laverdia. Its addition to our portfolio will expand Dechra into a new, niche therapy area, while also offering veterinarians and dog owners a simple to use, effective medication for lymphoma that extends the time a family has with their pet."
Dechra's share price rose by 2.7% to 4,414.00 pence each in London on Tuesday morning.
By Elizabeth Winter; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
DPH.L